Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27578836 | 0.93 | LMNA (0.50) | KMT2AMEN1ACHELMNAGAA | |
| SCHEMBL28389846 | 0.91 | LMNA (0.61) | KMT2AMEN1ACHECYP3A4LMNA | |
| SCHEMBL27772417 | 0.89 | FFAR1 (0.40) | KMT2AMEN1ACHENPC1RAB9A | |
| SCHEMBL7415225 | 0.87 | ALDH1A1 (0.43) | KMT2AACHECYP3A4LMNAGAA | |
| SCHEMBL2448081 | 0.86 | L3MBTL1 (0.47) | KMT2ALMNAHPGDGAANPC1 | |
| SCHEMBL28220738 | 0.85 | ACHE (0.47) | KMT2AMEN1ACHECYP3A4LMNA | |
| SCHEMBL27418279 | 0.84 | MGLL (0.48) | — | |
| SCHEMBL7868078 | 0.82 | PPARG (0.49) | KMT2AACHE | |
| SCHEMBL10782553 | 0.78 | ACHE (0.71) | KMT2AMEN1ACHECYP3A4LMNA | |
| SCHEMBL7868075 | 0.78 | GPR52 (0.42) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401918-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BIODEGRADABLE POLY(BETA-AMINO ESTERS) | MASSACHUSETTS INST TECHNOLOGY (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20150283051-A1 | DERIVATIVE OF NOVEL POLYHYDROXY AROMATIC COMPOUND AND USE THEREOF | RNS CO.,LTD. (KR) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283051-A1 | DERIVATIVE OF NOVEL POLYHYDROXY AROMATIC COMPOUND AND USE THEREOF | HRH3, CBR3, H1-0 | KMT2A 580/4885MEN1 4684/4885ACHE 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.